Divalproex sodium contraindications: Difference between revisions
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Divalproex sodium}} {{CMG}} ==Title <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DEPAKOTE (DIVALPROEX SODIUM) TABLET, DELAYED RE...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Contraindications== | ||
Depakote should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions(5.1)]. | |||
Depakote is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder[see Warnings and Precautions (5.1)]. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DEPAKOTE (DIVALPROEX SODIUM) TABLET, DELAYED RELEASE [ABBVIE INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=08a65cf4-7749-4ceb-6895-8f4805e2b01f | publisher = | date = | accessdate = }}</ref> | Depakote is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.13)]. | ||
Depakote is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)]. | |||
Depakote is contraindicated for use in prophylaxis of migraine headaches in pregnant women [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DEPAKOTE (DIVALPROEX SODIUM) TABLET, DELAYED RELEASE [ABBVIE INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=08a65cf4-7749-4ceb-6895-8f4805e2b01f | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 03:04, 7 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Contraindications
Depakote should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions(5.1)].
Depakote is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder[see Warnings and Precautions (5.1)].
Depakote is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.13)].
Depakote is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)].
Depakote is contraindicated for use in prophylaxis of migraine headaches in pregnant women [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1)].[1]
References
Adapted from the FDA Package Insert.